As you ruminate, what about the possibility of the sequence of 1) PFE breakup into "innovative core pharma" company + ROW branded generic/legacy product +sell small parts...and then 2) then the noncore company partners with MNTA. This solves the conflict of interest discussed by Wheeler at GS. Then that part of the company would be the much more intriguing investment...